{"url_path":"/sec/pstv/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-226978-index.html","accession_number":"0001193125-26-226978","cik":"0001095981","ticker":"PSTV","issuer_name":"PLUS THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-226978-index.html","primary_entity_key":"0001095981","primary_entity_name":"PLUS THERAPEUTICS, INC."},"word_count":687,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nEXHIBIT INDEX\n\nPLUS THERAPEUTICS, INC.\n\n \n\nExhibit Number\n\nExhibit Title\n\nFiled with this Form 10-Q\n\nIncorporated by Reference\n\nForm\n\nFile No.\n\nDate Filed\n\n3.1\n\n[Composite Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/0001095981/000114036116057505/ex3_1.htm)\n\n10-K\n\n001-34375\n\n Exhibit 3.1\n\n03/11/2016\n\n3.2\n\n[Certificate of Amendment to Amended and Restated Certificate](https://www.sec.gov/Archives/edgar/data/0001095981/000109598116000063/ex3_1.htm)\n\n8-K\n\n001-34375\n\n Exhibit 3.1\n\n05/10/2016\n\n3.3\n\n[Certificate of Amendment to Amended and Restated Certificate](https://www.sec.gov/Archives/edgar/data/0001095981/000156459018014245/cytx-ex31_6.htm)\n\n8-K\n\n001-34375\n\n Exhibit 3.1\n\n05/23/2018\n\n3.4\n\n[Certificate of Amendment to Amended and Restated Certificate](https://www.sec.gov/Archives/edgar/data/1095981/000156459019026454/cytx-ex31_6.htm)\n\n8-K\n\n001-34375\n\n Exhibit 3.1\n\n07/29/2019\n\n3.5\n\n[Certificate of Amendment to Amended and Restated Certificate](https://www.sec.gov/Archives/edgar/data/0001095981/000156459019028996/pstv-ex31_18.htm)\n\n8-K\n\n001-34375\n\n Exhibit 3.1\n\n08/06/2019\n\n3.6\n\n[Certificate of Amendment to Amended and Restated Certificate](https://www.sec.gov/Archives/edgar/data/0001095981/000119312523127227/d475493dex31.htm)\n\n \n\n8-K\n\n001-34375\n\n Exhibit 3.1\n\n04/28/2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n3.7\n\n[Certificate of Amendment to the Certificate of Incorporation, as amended](https://www.sec.gov/Archives/edgar/data/1095981/000095017025062742/pstv-ex3_1.htm)\n\n \n\n8-K\n\n001-34375\n\n Exhibit 3.1\n\n05/02/2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n3.8\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on April 1, 2026](pstv-ex3_8.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.9\n\n[Certificate of Correction to the Amended and Restated Certificate filed with the Delaware Secretary of State on May 12, 2026](pstv-ex3_9.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.10\n\n[Amended and Restated Bylaws of Plus Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/0001095981/000119312521277718/d164672dex31.htm)\n\n8-K\n\n001-34375\n\nExhibit 3.1\n\n09/21/2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n3.11\n\n[Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock](https://www.sec.gov/Archives/edgar/data/1095981/000156459017024297/cytx-ex31_6.htm)\n\n \n\n8-K\n\n001-34375\n\nExhibit 3.1\n\n11/28/2017\n\n \n\n \n\n \n\n \n\n \n\n \n\n3.12\n\n[Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock](https://www.sec.gov/Archives/edgar/data/1095981/000156459018017443/cytx-ex31_7.htm)\n\n \n\n8-K\n\n001-34375\n\nExhibit 3.1\n\n07/25/2018\n\n \n\n \n\n \n\n \n\n \n\n \n\n3.13\n\n[2020 Stock Incentive Plan, as amended and restated on May 14, 2026](pstv-ex3_13.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.1\n\n[Description of Securities](https://www.sec.gov/Archives/edgar/data/1095981/000156459020014165/pstv-ex41_202.htm)\n\n \n\n10-K\n\n001-34375\n\nExhibit 4.1\n\n03/30/2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.2\n\n[Form of Common Stock Certificate](https://www.sec.gov/Archives/edgar/data/1095981/000156459018005136/cytx-ex433_277.htm)\n\n \n\n10-K\n\n001-34375\n\nExhibit 4.33\n\n03/09/2018\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.3\n\n[Form of Pre-Funded Warrant](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001095981/000119312524135399/d827838d8k.htm)\n\n \n\n8-K\n\n001-34375\n\nExhibit 4.1\n\n05/09/2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.4\n\n[Form of Amendment and Restatement of the May 2024 Series A Warrant](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001095981/000095017024097091/pstv-20240630.htm)\n\n \n\n10-Q\n\n011-34375\nExhibit 4.7\n\n08/14/2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.5\n\n[Form of Amendment and Restatement of the May 2024 Series B Warrant](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001095981/000095017024097091/pstv-20240630.htm)\n\n \n\n10-Q\n\n011-34375\nExhibit 4.8\n\n08/14/2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.6\n\n[Form of Pre-Funded Warrant](https://www.sec.gov/Archives/edgar/data/1095981/000119312525028151/d916701dex41.htm)\n\n \n\n8-K\n\n011-34375\nExhibit 4.1\n\n02/18/2025\n\n35\n\n[Table of Contents](#table_of_contents)\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.7\n\n[Form of Warrant issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein](https://www.sec.gov/Archives/edgar/data/1095981/000119312525028151/d916701dex42.htm)\n\n \n\n8-K\n\n001-34375\n\nExhibit 4.2\n\n02/18/2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.8\n\n[Form of Pre-Funded Warrant](https://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/d875007dex41.htm)\n\n \n\n8-K\n\n \n\n001-34375\n\nExhibit 4.1\n\n03/04/2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.9\n\n[Form of Amended March 2025 Series B Warrant](https://www.sec.gov/Archives/edgar/data/1095981/000119312525142093/d942989dex41.htm)\n\n \n\n8-K\n\n \n\n001-34375\n\nExhibit 4.1\n\n06/17/2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n4.10\n\n[Form of Warrant, dated January 15, 2026](https://www.sec.gov/Archives/edgar/data/1095981/000119312525178940/d942543dex1041.htm)\n\n \n\n8-K\n\n001-34375\n\nExhibit 4.1\n\n01/16/2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-1.04(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](pstv-ex31_1.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](pstv-ex31_2.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1*\n\n[Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002](pstv-ex32_1.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\nX\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\nX\n\n104\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\nX\n\n \n\n* In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No. 34‑47986, the certifications furnished in Exhibits 31.1, 31.2 and 32.1 hereto are deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates them by reference.\n\n \n\n \n\n36\n\n[Table of Contents](#table_of_contents)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nPLUS THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Marc H. Hedrick\n\nDated: May 15, 2026\n\n \n\n \n\n \n\nMarc H. Hedrick\n\n \n\n \n\n \n\n \n\nPresident & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Andrew Sims\n\nDated: May 15, 2026\n\n \n\n \n\n \n\nAndrew Sims\n\n \n\n \n\n \n\n \n\nChief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer)\n\n \n\n \n\n \n\n37"}